Here's Why Acceleron Pharma Inc. Lost 10.2% in July

Shares of Acceleron Pharma (NASDAQ: XLRN) lost over 10% last month, according to data provided by S&P Global Market Intelligence, but it's not nearly as bad as it looks. Investors simply adjusted the company's market valuation following a huge one-day surge of 42% at the end of June, when the biopharma announced positive results for a phase 3 trial evaluating its lead drug candidate.